Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:APGE NASDAQ:AXSM NASDAQ:LEGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$86.79-2.8%$55.05$4.77▼$92.91$6.56B0.58686,751 shs363,787 shsAPGEApogee Therapeutics$37.68-2.0%$38.32$26.20▼$63.50$1.74B1.42716,845 shs150,613 shsAXSMAxsome Therapeutics$124.35-1.1%$111.18$75.56▼$139.13$6.22B0.54758,312 shs202,170 shsLEGNLegend Biotech$33.48-2.3%$37.85$27.34▼$52.31$6.19B0.281.43 million shs1.69 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-0.83%+8.85%+27.26%+1,102.83%+643.75%APGEApogee Therapeutics+0.10%+1.58%+8.67%-9.38%-19.05%AXSMAxsome Therapeutics-2.79%+1.79%+19.92%+16.28%+33.57%LEGNLegend Biotech-1.07%+0.09%-7.43%-6.40%-31.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$86.79-2.8%$55.05$4.77▼$92.91$6.56B0.58686,751 shs363,787 shsAPGEApogee Therapeutics$37.68-2.0%$38.32$26.20▼$63.50$1.74B1.42716,845 shs150,613 shsAXSMAxsome Therapeutics$124.35-1.1%$111.18$75.56▼$139.13$6.22B0.54758,312 shs202,170 shsLEGNLegend Biotech$33.48-2.3%$37.85$27.34▼$52.31$6.19B0.281.43 million shs1.69 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-0.83%+8.85%+27.26%+1,102.83%+643.75%APGEApogee Therapeutics+0.10%+1.58%+8.67%-9.38%-19.05%AXSMAxsome Therapeutics-2.79%+1.79%+19.92%+16.28%+33.57%LEGNLegend Biotech-1.07%+0.09%-7.43%-6.40%-31.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.11Buy$95.149.62% UpsideAPGEApogee Therapeutics 2.88Moderate Buy$97.29158.19% UpsideAXSMAxsome Therapeutics 3.13Buy$177.8643.03% UpsideLEGNLegend Biotech 2.91Moderate Buy$74.22121.72% UpsideCurrent Analyst Ratings BreakdownLatest APGE, LEGN, ABVX, and AXSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ABVXAbivaxBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$112.009/3/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$163.008/28/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/28/2025APGEApogee TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$78.00 ➝ $87.008/27/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$66.008/25/2025LEGNLegend BiotechJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$77.00 ➝ $78.008/14/2025APGEApogee TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/12/2025LEGNLegend BiotechRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$75.00 ➝ $77.008/12/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$81.00 ➝ $83.008/11/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$90.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/AAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/AAXSMAxsome Therapeutics$495.03M12.53N/AN/A$1.18 per share105.38LEGNLegend Biotech$796.84M7.75N/AN/A$5.70 per share5.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/AAPGEApogee Therapeutics-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%11/11/2025 (Estimated)AXSMAxsome Therapeutics-$287.22M-$5.07N/A44.10N/A-49.88%-283.22%-33.06%11/11/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)Latest APGE, LEGN, ABVX, and AXSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/8/2025Q2 2025ABVXAbivax-$0.90-$0.86+$0.04-$0.86$1.35 millionN/A8/11/2025Q2 2025APGEApogee Therapeutics-$1.03-$1.13-$0.10-$1.13N/AN/A8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAPGEApogee TherapeuticsN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25APGEApogee TherapeuticsN/A16.3616.36AXSMAxsome Therapeutics1.661.571.51LEGNLegend Biotech0.304.714.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%APGEApogee Therapeutics79.04%AXSMAxsome Therapeutics81.49%LEGNLegend Biotech70.89%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAPGEApogee Therapeutics42.77%AXSMAxsome Therapeutics22.40%LEGNLegend Biotech0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6175.57 millionN/ANot OptionableAPGEApogee Therapeutics9146.11 million26.39 millionOptionableAXSMAxsome Therapeutics38049.90 million38.72 millionOptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionableAPGE, LEGN, ABVX, and AXSM HeadlinesRecent News About These CompaniesLegend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9 at 12:03 AM | seekingalpha.comAlliancebernstein L.P. Purchases 32,101 Shares of Legend Biotech Corporation Sponsored ADR $LEGNSeptember 9 at 4:57 AM | marketbeat.comCinctive Capital Management LP Sells 11,869 Shares of Legend Biotech Corporation Sponsored ADR $LEGNSeptember 8 at 5:47 AM | marketbeat.comNomura Holdings Inc. Buys New Position in Legend Biotech Corporation Sponsored ADR $LEGNSeptember 8 at 4:24 AM | marketbeat.comLegend Biotech in talks for listing outside U.S., Bloomberg saysSeptember 6, 2025 | msn.comLegend Biotech Considering Second Listing Outside US: ReportSeptember 6, 2025 | msn.comLegend Biotech (NASDAQ:LEGN) Stock Price Up 5.4% - What's Next?September 5, 2025 | marketbeat.comTrexquant Investment LP Makes New Investment in Legend Biotech Corporation Sponsored ADR $LEGNSeptember 5, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Purchases Shares of 40,400 Legend Biotech Corporation Sponsored ADR $LEGNSeptember 3, 2025 | marketbeat.comFY2025 EPS Forecast for Legend Biotech Lowered by AnalystAugust 31, 2025 | marketbeat.comCantor Fitzgerald Expects Weaker Earnings for Legend BiotechAugust 31, 2025 | americanbankingnews.comThe Bull Case For Legend Biotech (LEGN) Could Change Following Appointment of CFO With Global Pharma ExpertiseAugust 30, 2025 | uk.finance.yahoo.comTema Etfs LLC Acquires 40,646 Shares of Legend Biotech Corporation Sponsored ADR $LEGNAugust 30, 2025 | marketbeat.comJump Financial LLC Sells 102,241 Shares of Legend Biotech Corporation Sponsored ADR $LEGNAugust 30, 2025 | marketbeat.comCantor Fitzgerald Reaffirms "Overweight" Rating for Legend Biotech (NASDAQ:LEGN)August 29, 2025 | marketbeat.com170,186 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Nuveen LLCAugust 28, 2025 | marketbeat.comLegend Biotech assumed with an Overweight at Cantor FitzgeraldAugust 27, 2025 | msn.comLegend Biotech (NASDAQ:LEGN) Given New $78.00 Price Target at JPMorgan Chase & Co.August 27, 2025 | marketbeat.comLegend Biotech's Surging Revenue Fuels Analyst Confidence Despite Ongoing LossesAugust 26, 2025 | aktiencheck.deALegend Biotech to Participate in the Morgan Stanley Global Healthcare ConferenceAugust 26, 2025 | markets.businessinsider.comPrice T Rowe Associates Inc. MD Trims Stock Position in Legend Biotech Corporation Sponsored ADR $LEGNAugust 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPGE, LEGN, ABVX, and AXSM Company DescriptionsAbivax NASDAQ:ABVX$86.79 -2.46 (-2.76%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Apogee Therapeutics NASDAQ:APGE$37.68 -0.78 (-2.03%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Axsome Therapeutics NASDAQ:AXSM$124.38 -1.30 (-1.04%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Legend Biotech NASDAQ:LEGN$33.52 -0.73 (-2.14%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
